TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33015194

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Hypoglycemia prediction model
Number of subjects: 257
Study: 33181631

Group type: EXPERIMENTAL
Intervention: Aphakic eyes
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Pseudophakic eyes
Number of subjects: 114

Group type: COMPARATOR
Intervention: Normal eyes
Number of subjects: 114
Study: 34469399

Group type: EXPERIMENTAL
Intervention: SSP‐App program (experimental group)
Number of subjects: 107

Group type: COMPARATOR
Intervention: No experimental treatment program (control group)
Number of subjects: 107
Study: 34144460

Group type: EXPERIMENTAL
Intervention: Early care (EC) with follow-up in first seizure clinic (FSC) within 3 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Late care (LC) with follow-up in FSC after 4 months
Number of subjects: 52

Group type: COMPARATOR
Intervention: Children with febrile seizures (FS)
Number of subjects: 52
Study: 36152481

Group type: EXPERIMENTAL
Intervention: General-digital-alteration label
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Health-warning label
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Specific-weight label
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Facial features/cosmetic label
Number of subjects: 872

Group type: COMPARATOR
Intervention: No label
Number of subjects: 872
Study: 34162019

Group type: EXPERIMENTAL
Intervention: Unani formulations
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (PUVAsol)
Number of subjects: 82
Study: 33809996

Group type: EXPERIMENTAL
Intervention: L-Glutamine supplementation (Gln) with physical exercises (PE + Gln)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: L-Glutamine supplementation (Gln) without physical exercises (NPE + Gln)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: L-Glutamine supplementation (Gln)
Number of subjects: 44
Study: 32134713

Group type: EXPERIMENTAL
Intervention: Resveratrol (250 mg tablet)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Estradiol (0.05 mg/day transdermal patch)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 35263341

Group type: EXPERIMENTAL
Intervention: Combined (music & ABS; n = 39)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Music‐alone (n = 36)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: ABS‐alone (n = 41)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Pink noise (control; n = 47)
Number of subjects: 163
Study: 35010287

Group type: EXPERIMENTAL
Intervention: Multicomponent training combined with flexibility training (CT)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Multicomponent training (MT)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 3
Study: 35798893

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (AC)
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Surgery-only
Number of subjects: 1012
Study: 35709465

Group type: EXPERIMENTAL
Intervention: Gemcitabine and cisplatin induction chemotherapy before concurrent chemoradiotherapy
Number of subjects: 480

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy alone (standard therapy)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Gemcitabine and cisplatin induction chemotherapy
Number of subjects: 480
Study: 33092573

Group type: EXPERIMENTAL
Intervention: Op‐reha Guide (specialised rehabilitation)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Usual rehabilitation (control group)
Number of subjects: 135
Study: 33046233

Group type: EXPERIMENTAL
Intervention: Left ventricular reshaping with a beating heart implant
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no implant)
Number of subjects: 38
Study: 34066784

Group type: EXPERIMENTAL
Intervention: Nab-FOLFIRI
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Nab-FOLFOX
Number of subjects: 84
Study: 32756952

Group type: EXPERIMENTAL
Intervention: Increasing BMI in women with PCOS
Number of subjects: 1561

Group type: COMPARATOR
Intervention: Increasing BMI in ovulatory controls (OVAs)
Number of subjects: 1561

Group type: EXPERIMENTAL
Intervention: Increasing BMI in PCOS
Number of subjects: 1561

Group type: EXPERIMENTAL
Intervention: Body surface area (BSA)
Number of subjects: 1561

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 1561
Study: 33895221

Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Retrolaminar Block (RLB)
Number of subjects: 80
Study: 34587986

Group type: EXPERIMENTAL
Intervention: Brazilian cardioprotective diet and nuts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32897359

Group type: EXPERIMENTAL
Intervention: Measles vaccination
Number of subjects: 8319

Group type: COMPARATOR
Intervention: Health check-up
Number of subjects: 8319
Study: 35786597

Group type: COMPARATOR
Intervention: Nivolumab (NIVO) first-line therapy in combination with chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nivolumab (NIVO) third-line or later monotherapy
Number of subjects: 0
Study: 32068914

Group type: EXPERIMENTAL
Intervention: Licogliflozin 10 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Licogliflozin 50 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Empagliflozin (25 mg)
Number of subjects: 125
Study: 35858190

Group type: EXPERIMENTAL
Intervention: Telehealth application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study: 34008203

Group type: EXPERIMENTAL
Intervention: Blood donors (n = 2,600)
Number of subjects: 5100

Group type: EXPERIMENTAL
Intervention: Pregnant women (n = 2,500)
Number of subjects: 5100

Group type: EXPERIMENTAL
Intervention: Seropositive healthy donors (n = 56)
Number of subjects: 5100

Group type: COMPARATOR
Intervention: Historical controls (n = 595)
Number of subjects: 5100
Study: 35622105

Group type: EXPERIMENTAL
Intervention: Intermittent Sequential Pneumatic Compression (ISPC) device
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no device)
Number of subjects: 50
Study: 34108173

Group type: EXPERIMENTAL
Intervention: Coach-supported, interactive mHealth platform for self-management of dementia risk factors
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Static control platform
Number of subjects: 2400
Study: 34318635

Group type: EXPERIMENTAL
Intervention: Parecoxib sodium preemptive analgesia
Number of subjects: 70

Group type: COMPARATOR
Intervention: Indomethacin suppository (0.1 g/suppository)
Number of subjects: 70
Study: 33071153

Group type: EXPERIMENTAL
Intervention: Heat-activated NiTi archwires at 35°C
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Heat-activated NiTi archwires at 37°C
Number of subjects: 54
Study: 35279835

Group type: EXPERIMENTAL
Intervention: Inclisiran
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCSK9-inhibiting monoclonal antibodies
Number of subjects: 0
Study: 33230873

Group type: EXPERIMENTAL
Intervention: 2 mm height abutment during surgical stage (Group A)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 1 mm height abutment during surgical stage (Group B)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 2 mm height abutment after 2 months (Group C)
Number of subjects: 29
Study: 33097016

Group type: EXPERIMENTAL
Intervention: Cash Transfers (CTs)
Number of subjects: 2909
Study: 34520608

Group type: EXPERIMENTAL
Intervention: Menthol (3 mM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 34749739

Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg daily on top of standard of care for 28 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard of care only for 28 days
Number of subjects: 28
Study: 35440808

Group type: EXPERIMENTAL
Intervention: Home blood pressure in the evening
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Home blood pressure in the morning
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Office blood pressure before treatment
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Office blood pressure in the on-treatment follow-up period
Number of subjects: 252
Study: 34656663

Group type: EXPERIMENTAL
Intervention: Right-sided CVAD insertion
Number of subjects: 2786

Group type: COMPARATOR
Intervention: Left-sided CVAD insertion
Number of subjects: 2786
Study: 35546563

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 32183902

Group type: EXPERIMENTAL
Intervention: Multi-component implementation support strategy for PA4E1 program
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Quantitative data collection from Physical Education teachers, in-School Champions, students
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Qualitative data collection through semi-structured interviews and focus groups
Number of subjects: 38
Study: 35580165

Group type: EXPERIMENTAL
Intervention: CBT‐I+Light
Number of subjects: 101

Group type: COMPARATOR
Intervention: TAU+
Number of subjects: 101
Study: 33632085

Group type: EXPERIMENTAL
Intervention: miR-18a and PD-L1 levels in HPV-positive cervical cancer patients (observation group)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Vaginal microecology in HPV-positive cervical cancer patients (observation group)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Vaginal microecology in healthy women (control group)
Number of subjects: 382

Group type: COMPARATOR
Intervention: miR-18a and PD-L1 levels in healthy women (control group)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: miR-18a and PD-L1 levels in patients at stage III (observation group)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Diagnostic value of miR-18a and PD-L1
Number of subjects: 382
Study: 32245274

Group type: EXPERIMENTAL
Intervention: Comprehensive SRH/family planning intervention
Number of subjects: 2100
Study: 35075723

Group type: EXPERIMENTAL
Intervention: Topical/nasal administration of a probiotic assemblage (PA) of Lactobacillus rhamnosus SP1, Lactobacillus paracasei 101/37 and Lactococcus lactis L1A
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 34933930

Group type: EXPERIMENTAL
Intervention: Three potentially neuroprotective drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32320144

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 0
Study: 36502286

Group type: EXPERIMENTAL
Intervention: Morning exercise (AMEx)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Evening exercise (PMEx)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Wait-list control (CON)
Number of subjects: 100
Study: 33119790

Group type: EXPERIMENTAL
Intervention: 500 mg vitamin C
Number of subjects: 74

Group type: COMPARATOR
Intervention: Sterile water (control)
Number of subjects: 74
Study: 32251223

Group type: EXPERIMENTAL
Intervention: Auricular acupressure (5 days/week for 4 weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 56
Study: 33741876

Group type: EXPERIMENTAL
Intervention: Soccer-related injuries in players aged 12 to 18
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soccer-related injuries in players aged 6 to 11
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soccer-related injuries in players aged 19 to 34
Number of subjects: 0
Study: 32106869

Group type: EXPERIMENTAL
Intervention: Oral (PO) administration of diclofenac
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) administration of diclofenac
Number of subjects: 38

Group type: COMPARATOR
Intervention: Undesired route (either PO or IM)
Number of subjects: 38
Study: 35689284

Group type: EXPERIMENTAL
Intervention: Knee sleeve worn for 6 weeks at least 1 hour daily (Sleeve Group, n=9)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (n=9) did not wear the knee sleeve
Number of subjects: 31
Study: 35129469

Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) 1200 mg twice-daily for up to 5 days postoperatively
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 32880953

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy Skills Training Group (DBT‐ST), n=16
Number of subjects: 31

Group type: COMPARATOR
Intervention: Treatment as usual (TaU), n=15
Number of subjects: 31
Study: 36177827

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (SpA) with clonidine
Number of subjects: 135

Group type: COMPARATOR
Intervention: Epidural analgesia (EDA)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (SpA)
Number of subjects: 135
Study: 33853609

Group type: EXPERIMENTAL
Intervention: Collaborative mode
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Competitive mode
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Co-active mode
Number of subjects: 21
Study: 33183673

Group type: EXPERIMENTAL
Intervention: Grape Juice (GJ)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (WB)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study: 32367254

Group type: EXPERIMENTAL
Intervention: Physical activity and dietary intervention
Number of subjects: 504

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 504
Study: 32183250

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 36882134

Group type: EXPERIMENTAL
Intervention: Alert during individual patient encounters
Number of subjects: 2211

Group type: EXPERIMENTAL
Intervention: Message about multiple patients between encounters
Number of subjects: 2211

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 2211

Group type: COMPARATOR
Intervention: Alert vs Usual Care
Number of subjects: 2211

Group type: EXPERIMENTAL
Intervention: Alert vs Message
Number of subjects: 2211

Group type: EXPERIMENTAL
Intervention: Alert
Number of subjects: 2211
Study: 34303417

Group type: EXPERIMENTAL
Intervention: Interactive educational sessions and use of a dialogue tool
Number of subjects: 1470

Group type: COMPARATOR
Intervention: Standard practice (control group)
Number of subjects: 1470
Study: 32605784

Group type: EXPERIMENTAL
Intervention: Nail/Plate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dual-Plate
Number of subjects: 10
Study: 35148434

Group type: EXPERIMENTAL
Intervention: ActiveHip+ rehabilitation (N=52)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (N=52)
Number of subjects: 104
Study: 35234890

Group type: EXPERIMENTAL
Intervention: Tailored message condition
Number of subjects: 738

Group type: COMPARATOR
Intervention: Control message condition
Number of subjects: 738
Study: 34386281

Group type: EXPERIMENTAL
Intervention: Dynamic Innovative Balance System (DIBA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (balance training using a balance board, a wobble board, the BOSU, or a soft cushion block)
Number of subjects: 36
Study: 32265432

Group type: EXPERIMENTAL
Intervention: Informational video about anesthesia
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (no video)
Number of subjects: 121
Study: 35615893

Group type: EXPERIMENTAL
Intervention: 3-month telerehabilitation
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study: 33562129

Group type: EXPERIMENTAL
Intervention: Health education intervention on hearing health (3 months duration)
Number of subjects: 830

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 830
Study: 32212518

Group type: EXPERIMENTAL
Intervention: Luspatercept (1.00 to 1.25 mg/kg)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Luspatercept
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study: 34021599

Group type: EXPERIMENTAL
Intervention: Sedentary time (ST, min/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 80
Study: 32268583

Group type: EXPERIMENTAL
Intervention: Usual nutrient intakes and food sources assessment
Number of subjects: 1264

Group type: EXPERIMENTAL
Intervention: Dietary diversity questionnaire and physical activity assessment
Number of subjects: 1264

Group type: EXPERIMENTAL
Intervention: Top food sources of energy
Number of subjects: 1264
Study: 35011579

Group type: EXPERIMENTAL
Intervention: Sunitinib or Pazopanib (anti-angiogenic drugs)
Number of subjects: 86
Study: 35839108

Group type: EXPERIMENTAL
Intervention: Phenylephrine combined with Goal-Directed Fluid Therapy (GDFT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Goal-Directed Fluid Therapy (GDFT) alone
Number of subjects: 80
Study: 33545615

Group type: EXPERIMENTAL
Intervention: Weighted genetic risk scores (WGRSs) for PLT
Number of subjects: 17037

Group type: COMPARATOR
Intervention: Chemerin level WGRSs
Number of subjects: 17037
Study: 33230026

Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5-3 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32885482

Group type: EXPERIMENTAL
Intervention: Overdentures retained by 1 implant (Group I)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Overdentures retained by 2 implants (Group II)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Fixed hybrid prosthesis on 4 implants (Group III)
Number of subjects: 37
Study: 34127158

Group type: EXPERIMENTAL
Intervention: Schema therapy (ST)
Number of subjects: 103
Study: 33571369

Group type: EXPERIMENTAL
Intervention: Reduced RUTF
Number of subjects: 516

Group type: COMPARATOR
Intervention: Standard RUTF
Number of subjects: 516
Study: 32069294

Group type: EXPERIMENTAL
Intervention: Right anodal/left cathodal tDCS over the parietal cortex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right anodal/left cathodal tDCS over the prefrontal cortex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation (control)
Number of subjects: 0
Study: 35437251

Group type: EXPERIMENTAL
Intervention: Advanced Trauma Life Support (ATLS)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Primary Trauma Care (PTC)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 6
Study: 32729416

Group type: EXPERIMENTAL
Intervention: 5-immune gene pair signature (5-IRGPs)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: 5-IRGPs
Number of subjects: 542
Study: 32066490

Group type: EXPERIMENTAL
Intervention: Smartphone-based intervention
Number of subjects: 1696

Group type: COMPARATOR
Intervention: No intervention control
Number of subjects: 1696
Study: 35324465

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily with bevacizumab 10 mg/kg i.v. every 2 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Everolimus 10 mg daily
Number of subjects: 150
Study: 33377368

Group type: EXPERIMENTAL
Intervention: Chicken-based oral nutritional supplement (ONS)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (similarly flavored oral fluid)
Number of subjects: 38
Study: 35943744

Group type: EXPERIMENTAL
Intervention: Peer-led behavioral intervention from a certified peer recovery specialist (n=323)
Number of subjects: 648

Group type: COMPARATOR
Intervention: Standard intervention delivered by a hospital-employed licensed clinical social worker (n=325)
Number of subjects: 648
Study: 34956561

Group type: EXPERIMENTAL
Intervention: Anlotinib capsules combined with PD-1 inhibitor (camrelizumab)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Single treatment group (STG) with anlotinib only
Number of subjects: 88
Study: 32597302

Group type: EXPERIMENTAL
Intervention: PGx-guided treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional treatment
Number of subjects: 100
Study: 35701155

Group type: EXPERIMENTAL
Intervention: T2T tapering strategy (N=81)
Number of subjects: 122

Group type: COMPARATOR
Intervention: T2T no-tapering strategy (N=41)
Number of subjects: 122
Study: 32577299

Group type: EXPERIMENTAL
Intervention: Executive function training (3 times a week for 30 min for 12 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-intervention control
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Executive function training
Number of subjects: 30
Study: 36073613

Group type: EXPERIMENTAL
Intervention: Hemostatic therapy guided by viscoelastic hemostatic assays (VHA)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Hemostatic therapy guided by conventional coagulation tests (CCT)
Number of subjects: 187
Study: 34520230

Group type: EXPERIMENTAL
Intervention: Hepatectomy followed by 12 courses of adjuvant mFOLFOX6 chemotherapy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Hepatectomy alone
Number of subjects: 300
Study: 35990136

Group type: EXPERIMENTAL
Intervention: Group counseling based on positive psychology
Number of subjects: 210

Group type: COMPARATOR
Intervention: Conventional intervention measures (Control)
Number of subjects: 210
Study: 33159530

Group type: EXPERIMENTAL
Intervention: Neuromuscular blocking agents (NMBAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NMBAs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partial neuromuscular blockade
Number of subjects: 0
Study: 35173415

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.294% (EC90)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Ropivacaine concentration adjusted based on previous patient's response
Number of subjects: 58
Study: 32222079

Group type: EXPERIMENTAL
Intervention: Foster care intervention
Number of subjects: 337

Group type: COMPARATOR
Intervention: Institutional rearing
Number of subjects: 337
Study: 35253331

Group type: EXPERIMENTAL
Intervention: DIY RT‐CGM with parental remote monitoring
Number of subjects: 55

Group type: COMPARATOR
Intervention: isCGM plus usual diabetes care
Number of subjects: 55
Study: 32768967

Group type: EXPERIMENTAL
Intervention: Melatonin (MEL) 25 mg administered at noon and 30 min before bedtime for three months
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo administered at noon and 30 min before bedtime for three months
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Melatonin (MEL)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: COMPARATOR
Intervention: Melatonin (MEL) and Placebo
Number of subjects: 26
Study: 35641569

Group type: EXPERIMENTAL
Intervention: Digital support system with daily weight measurements
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 107